Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine plus Sorafenib in Advanced Biliary Tract Cancer
NCT00661830Phase 2Completed
- Start
- May 2008
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in biliary tract cancer (BTC) comparing Gemcitabine + Sorafenib with Gemcitabine + Placebo (2 arms). Primary endpoint: Progression-free Survival at 1 year. Started May 2008; status: completed.
02
Drugs
sorafenib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT00661830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00661830.